Cargando…
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937504/ https://www.ncbi.nlm.nih.gov/pubmed/29760563 http://dx.doi.org/10.2147/CMAR.S148009 |